Attenuation of β-amyloid-induced toxicity by sialic-acid-conjugated dendrimers: Role of sialic acid attachment

Brain Research

Volumn 1161, Issue 1, 2007, Pages 95-105

  Patel, Dhara A ^a   Henry, James E ^a   Good, Theresa A ^a  

^a University of Marylandw Baltimore County   (United States)

Author keywords

Alzheimer's disease; Amyloid; Dendrimer; Sialic acid; Toxicity

Indexed keywords

AMYLOID BETA PROTEIN; CARBOXYLIC ACID; HYDROXYL GROUP; SIALIC ACID;

ALZHEIMER DISEASE; ARTICLE; BINDING AFFINITY; CELL SURFACE; DEGENERATIVE DISEASE; HUMAN; HUMAN CELL; NEUROTOXICITY; PRIORITY JOURNAL; PROTEIN BINDING; SENILE PLAQUE;

AMYLOID BETA-PROTEIN; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL SURVIVAL; DENDRIMERS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; N-ACETYLNEURAMINIC ACID; NERVE GROWTH FACTOR; NEUROBLASTOMA; PEPTIDE FRAGMENTS;

EID: 34447513070     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2007.05.055     Document Type: Article

References (57)

1. Ariga T., and Yu R.K. GM1 inhibits amyloid beta-protein-induced cytokine release. Neurochem. Res. 24 (1999) 219-226
2. Ariga T., Kobayashi K., Hasegawa A., Kiso M., Ishida H., and Miyatake T. Characterization of high-affinity binding between gangliosides and amyloid beta-protein. Arch. Biochem. Biophys. 388 (2001) 225-230
3. Attrill H., Takazawa H., Witt S., Kelm S., Isecke R., Brossmer R., Ando T., Ishida H., Kiso M., Crocker P.R., and van Aalten D.M. The structure of siglec-7 in complex with sialosides: leads for rational structure-based inhibitor design. Biochem. J. 397 (2006) 271-278
4. Avdulov N.A., Chochina S.V., Igbavboa U., Warden C.S., Vassiliev A.V., and Wood W.G. Lipid binding to amyloid beta-peptide aggregates: preferential binding of cholesterol as compared with phosphatidylcholine and fatty acids. J. Neurochem. 69 (1997) 1746-1752
5. Bard F., Cannon C., Barbour R., Burke R.L., Games D., Grajeda H., Guido T., Hu K., Huang J., Johnson-Wood K., Khan K., Kholodenko D., Lee M., Lieberburg I., Motter R., Nguyen M., Soriano F., Vasquez N., Weiss K., Welch B., Seubert P., Schenk D., and Yednock T. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat. Med. 6 (2000) 916-919
6. Bergamaschini L., Rossi E., Storini C., Pizzimenti S., Distaso M., Perego C., De Luigi A., Vergani C., and De Simoni M.G. Peripheral treatment with enoxaparin, a low molecular weight heparin, reduces plaques and beta-amyloid accumulation in a mouse model of Alzheimer's disease. J. Neurosci. 24 (2004) 4181-4186
7. Bhavanandan V.P., and Sheykhnazari M. Adaptation of the periodate-resorcinol method for determination of sialic acids to a microassay using microtiter plate reader. Anal. Biochem. 213 (1993) 438-440
8. Blanchard B.J., Chen A., Rozeboom L.M., Stafford K.A., Weigele P., and Ingram V.M. Efficient reversal of Alzheimer's disease fibril formation and elimination of neurotoxicity by a small molecule. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 14326-14332
9. Blumberg P.M. Protein kinase C as the receptor for the phorbol ester tumor promoters: sixth Rhoads memorial award lecture. Cancer Res. 48 (1988) 1-8
10. Choksakulnimitr S., Masuda S., Tokuda H., Takakura Y., and Hashida M. In vitro cytotoxicity of macromolecules in different cell culture systems. J. Control. Release 34 (1995) 233-241
11. Choo-Smith L.P., Garzon-Rodriguez W., Glabe C.G., and Surewicz W.K. Acceleration of amyloid fibril formation by specific binding of Abeta-(1-40) peptide to ganglioside-containing membrane vesicles. J. Biol. Chem. 272 (1997) 22987-22990
12. Dahlgren K.N., Manelli A.M., Stine Jr. W.B., Baker L.K., Krafft G.A., and LaDu M.J. Oligomeric and fibrillar species of amyloid-beta peptides differentially affect neuronal viability. J. Biol. Chem. 277 (2002) 32046-32053
13. DeMattos R.B., Bales K.R., Cummins D.J., Dodart J.C., Paul S.M., and Holtzman D.M. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 8850-8855
14. Drouet B., Pincon-Raymond M., Chambaz J., and Pillot T. Laminin 1 attenuates beta-amyloid peptide Abeta(1-40) neurotoxicity of cultured fetal rat cortical neurons. J. Neurochem. 73 (1999) 742-749
15. Ernst R.L., and Hay J.W. The US economic and social costs of Alzheimer's disease revisited. Am. J. Public Health 84 (1994) 1261-1264
16. Etcheberrigaray R., Tan M., Dewachter I., Kuiperi C., Van der Auwera I., Wera S., Qiao L., Bank B., Nelson T.J., Kozikowski A.P., Van Leuven F., and Alkon D.L. Therapeutic effects of PKC activators in Alzheimer's disease transgenic mice. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 11141-11146
17. Fischer D., Li Y., Ahlemeyer B., Krieglstein J., and Kissel T. In vitro cytotoxicity testing of polycations: influence of polymer structure on cell viability and hemolysis. Biomaterials 24 (2003) 1121-1131
18. Gelinas D.S., DaSilva K., Fenili D., St George-Hyslop P., and McLaurin J. Immunotherapy for Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 101 Suppl. 2 (2004) 14657-14662
19. Ghanta J., Shen C.L., Kiessling L.L., and Murphy R.M. A strategy for designing inhibitors of beta-amyloid toxicity. J. Biol. Chem. 271 (1996) 29525-29528
20. Hartley D.M., Walsh D.M., Ye C.P., Diehl T., Vasquez S., Vassilev P.M., Teplow D.B., and Selkoe D.J. Protofibrillar intermediates of amyloid beta-protein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurons. J. Neurosci. 19 (1999) 8876-8884
21. Hebert L.E., Scherr P.A., Bienias J.L., Bennett D.A., and Evans D.A. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch. Neurol. 60 (2003) 1119-1122
22. Hertel C., Terzi E., Hauser N., Jakob-Rotne R., Seelig J., and Kemp J.A. Inhibition of the electrostatic interaction between beta-amyloid peptide and membranes prevents beta-amyloid-induced toxicity. Proc. Natl. Acad. Sci. U. S. A. 94 (1997) 9412-9416
23. Hock C., Konietzko U., Streffer J.R., Tracy J., Signorell A., Muller-Tillmanns B., Lemke U., Henke K., Moritz E., Garcia E., Wollmer M.A., Umbricht D., de Quervain D.J., Hofmann M., Maddalena A., Papassotiropoulos A., and Nitsch R.M. Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. Neuron 38 (2003) 547-554
24. Huskens J. Multivalent interactions at interfaces. Curr. Opin. Chem. Biol. 10 (2006) 537-543
25. Inaba S., Okada T., Konakahara T., and Kodaka M. Specific binding of amyloid-beta-protein to IMR-32 neuroblastoma cell membrane. J. Pept. Res. 65 (2005) 485-490
26. Kakio A., Nishimoto S.I., Yanagisawa K., Kozutsumi Y., and Matsuzaki K. Cholesterol-dependent formation of GM1 ganglioside-bound amyloid beta-protein, an endogenous seed for Alzheimer amyloid. J. Biol. Chem. 276 (2001) 24985-24990
27. Kakio A., Yano Y., Takai D., Kuroda Y., Matsumoto O., Kozutsumi Y., and Matsuzaki K. Interaction between amyloid beta-protein aggregates and membranes. J. Pept. Sci. 10 (2004) 612-621
28. Kayed R., Head E., Thompson J.L., McIntire T.M., Milton S.C., Cotman C.W., and Glabe C.G. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300 (2003) 486-489
29. Kumar P.V., Asthana A., Dutta T., and Jain N.K. Intracellular macrophage uptake of rifampicin loaded mannosylated dendrimers. J. Drug Target. 14 (2006) 546-556
30. Lee S., Carson K., Rice-Ficht A., and Good T. Hsp20, a novel alpha-crystallin, prevents Abeta fibril formation and toxicity. Protein Sci. 14 (2005) 593-601
31. Lee S., Carson K., Rice-Ficht A., and Good T. Small heat shock proteins differentially affect Abeta aggregation and toxicity. Biochem. Biophys. Res. Commun. 347 (2006) 527-533
32. Lees W.J., Spaltenstein A., Kingery-Wood J.E., and Whitesides G.M. Polyacrylamides bearing pendant alpha-sialoside groups strongly inhibit agglutination of erythrocytes by influenza A virus: multivalency and steric stabilization of particulate biological systems. J. Med. Chem. 37 (1994) 3419-3433
33. Mandavilli A. The amyloid code. Nat. Med. 12 (2006) 747-751
34. Matsuoka Y., Saito M., LaFrancois J., Saito M., Gaynor K., Olm V., Wang L., Casey E., Lu Y., Shiratori C., Lemere C., and Duff K. Novel therapeutic approach for the treatment of Alzheimer's disease by peripheral administration of agents with an affinity to beta-amyloid. J. Neurosci. 23 (2003) 29-33
35. Matsuzaki K., and Horikiri C. Interactions of amyloid beta-peptide (1-40) with ganglioside-containing membranes. Biochemistry 38 (1999) 4137-4142
36. McLaurin J., and Chakrabartty A. Membrane disruption by Alzheimer beta-amyloid peptides mediated through specific binding to either phospholipids or gangliosides. Implications for neurotoxicity. J. Biol. Chem. 271 (1996) 26482-26489
37. McLaurin J., Franklin T., Fraser P.E., and Chakrabartty A. Structural transitions associated with the interaction of Alzheimer beta-amyloid peptides with gangliosides. J. Biol. Chem. 273 (1998) 4506-4515
38. Mount C., and Downton C. Alzheimer disease: progress or profit?. Nat. Med. 12 (2006) 780-784
39. Patel D., Henry J., and Good T. Attenuation of beta-amyloid induced toxicity by sialic acid-conjugated dendrimeric polymers. Biochim. Biophys. Acta 1760 (2006) 1802-1809
40. Polizzotti B.D., and Kiick K.L. Effects of polymer structure on the inhibition of cholera toxin by linear polypeptide-based glycopolymers. Biomacromolecules 7 (2006) 483-490
41. Prieto M.J., Bacigalupe D., Pardini O., Amalvy J.I., Venturini C., Morilla M.J., and Romero E.L. Nanomolar cationic dendrimeric sulfadiazine as potential antitoxoplasmic agent. Int. J. Pharm. 326 (2006) 160-168
42. Reuter J.D., Myc A., Hayes M.M., Gan Z., Roy R., Qin D., Yin R., Piehler L.T., Esfand R., Tomalia D.A., and Baker Jr. J.R. Inhibition of viral adhesion and infection by sialic-acid-conjugated dendritic polymers. Bioconjugate Chem. 10 (1999) 271-278
43. Rymer D.L., and Good T.A. The role of G protein activation in the toxicity of amyloidogenic Abeta-(1-40), Abeta-(25-35), and bovine calcitonin. J. Biol. Chem. 276 (2001) 2523-2530
44. Schenk D., Hagen M., and Seubert P. Current progress in beta-amyloid immunotherapy. Curr. Opin. Immunol. 16 (2004) 599-606
45. Seilheimer B., Bohrmann B., Bondolfi L., Muller F., Stuber D., and Dobeli H. The toxicity of the Alzheimer's beta-amyloid peptide correlates with a distinct fiber morphology. J. Struct. Biol. 119 (1997) 59-71
46. Selkoe D.J. Alzheimer's disease: a central role for amyloid. J. Neuropathol. Exp. Neurol. 53 (1994) 438-447
47. Valdes-Gonzalez T., Inagawa J., and Ido T. Neuropeptides interact with glycolipid receptors: a surface plasmon resonance study. Peptides 22 (2001) 1099-1106
48. Wakabayashi M., Okada T., Kozutsumi Y., and Matsuzaki K. GM1 ganglioside-mediated accumulation of amyloid beta-protein on cell membranes. Biochem. Biophys. Res. Commun. 328 (2005) 1019-1023
49. Wang S.S., Rymer D.L., and Good T.A. Reduction in cholesterol and sialic acid content protects cells from the toxic effects of beta-amyloid peptides. J. Biol. Chem. 276 (2001) 42027-42034
50. Wang S.S., Becerra-Arteaga A., and Good T.A. Development of a novel diffusion-based method to estimate the size of the aggregated Abeta species responsible for neurotoxicity. Biotechnol. Bioeng. 80 (2002) 50-59
51. Ward R.V., Jennings K.H., Jepras R., Neville W., Owen D.E., Hawkins J., Christie G., Davis J.B., George A., Karran E.H., and Howlett D.R. Fractionation and characterization of oligomeric, protofibrillar and fibrillar forms of beta-amyloid peptide. Biochem. J. 348 Pt 1 (2000) 137-144
52. Williamson M.P., Suzuki Y., Bourne N.T., and Asakura T. Binding of amyloid beta-peptide to ganglioside micelles is dependent on histidine-13. Biochem. J. 397 (2006) 483-490
53. Wittmar M., Ellis J.S., Morell F., Unger F., Schumacher J.C., Roberts C.J., Tendler S.J., Davies M.C., and Kissel T. Biophysical and transfection studies of an amine-modified poly(vinyl alcohol) for gene delivery. Bioconjugate Chem. 16 (2005) 1390-1398
54. Woller E.K., and Cloninger M.J. The lectin-binding properties of six generations of mannose-functionalized dendrimers. Org. Lett. 4 (2002) 7-10
55. Woller E.K., Walter E.D., Morgan J.R., Singel D.J., and Cloninger M.J. Altering the strength of lectin binding interactions and controlling the amount of lectin clustering using mannose/hydroxyl-functionalized dendrimers. J. Am. Chem. Soc. 125 (2003) 8820-8826
56. Yanagisawa K., Odaka A., Suzuki N., and Ihara Y. GM1 ganglioside-bound amyloid beta-protein (A beta): a possible form of preamyloid in Alzheimer's disease. Nat. Med. 1 (1995) 1062-1066
57. Zhu C.W., Scarmeas N., Torgan R., Albert M., Brandt J., Blacker D., Sano M., and Stern Y. Longitudinal study of effects of patient characteristics on direct costs in Alzheimer disease. Neurology 67 (2006) 998-1005